Ax­o­vant: That pos­i­tive p-val­ue we re­port­ed yes­ter­day? Um, we screwed that up too

Yes­ter­day Ax­o­vant ex­ecs watched their stock price $AX­ON col­lapse af­ter the biotech found­ed by the youth­ful for­mer hedge fund man­ag­er Vivek Ra­maswamy was forced to con­cede that its lead drug was worth­less.

To­day, the com­pa­ny led by CEO David Hung fol­lowed up with the ex­tra­or­di­nar­i­ly em­bar­rass­ing ad­mis­sion that it man­aged to in­cor­rect­ly re­port the p val­ue for the one clear­ly pos­i­tive end­point they had tout­ed as a sign that the biotech’s sec­ond drug, nelotanserin, was wor­thy of a piv­otal tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.